Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

October 19, 2021

Study Completion Date

October 30, 2024

Conditions
Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic OligodendrogliomaGliosarcomaMixed GliomaRecurrent Adult Brain NeoplasmRecurrent Glioblastoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lapatinib

Given PO

DRUG

Lapatinib Ditosylate

Given PO

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical resection of tumor

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Commack, Commack

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

02215

Dana-Farber Cancer Institute, Boston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02101905 - Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Biotech Hunter | Biotech Hunter